Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centers-Reference-Cited by-同舟云学术

Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centers

Published:2013-01-28 Issue:8 Volume:48 Page:1065-1069
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Bazarbachi A,Labopin M,Ghavamzadeh A,Giebel S,Al-Zahrani H,Ladeb S,Leone G,Abdel-Rahman F,Liso V,Hamidieh A A,Rasheed W,Ibrahim A,Alabdulaaly A,Kyrcz-Krzemien S,Arnold R,Kharfan-Dabaja M A,Alimoghaddam K,Aljurf M,Mohty M

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt20131.pdf

Reference17 articles.

1. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113: 4179–4187.

2. Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27: 61–69.

3. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333.

4. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109: 3658–3666.

5. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102: 1232–1240.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. OUTCOME OF ALLOGENEIC BONE MARROW TRANSPLANT FOR IRAQI PATIENTS WITH ACUTE MYELOID LEUKEMIA;Wiadomości Lekarskie;2021

2. Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries;Bone Marrow Transplantation;2019-09-04

3. Trends in hematopoietic stem cell transplant activity in Lebanon;Hematology/Oncology and Stem Cell Therapy;2017-12

4. Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?;Transplantation Proceedings;2017-10

5. Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature;Experimental Hematology & Oncology;2017-08-09